The firm saw an improvement in progression-free survival for patients on the ivonescimab regimen and a trend toward improved overall survival.

PFS in Phase 3 HARMONi study was met with statistical significance, but OS was not. Click here to find out why SMMT stock is ...

A new targeted cancer drug, DB-1310, is showing early signs of effectiveness in patients with advanced solid tumors that have ...

MK-1084, Merck’s investigational KRAS G12C inhibitor, showed a manageable safety profile along with antitumor activity in the ...

The FDA biologics license application for patritumab deruxtecan in EGFR+ NSCLC has been withdrawn following discussions with ...

The conversation centred on the company’s latest developments and strategic direction in cancer therapies, with a particular ...

Ivonescimab helped cut the risk of lung tumor progression in half in a multi-country Phase 3 trial. But it hasn’t yet clearly ...

Merck KGaA’s antibody-drug conjugate (ADC), precemtabart tocentecan, has shown to be safe and tolerable in a Phase Ib trial.

Despite mixed results, analysts maintained faith in ivonescimab’s ability to cross over between Eastern and Western patient ...

Christopher Danes, PhD, discusses a study exploring the differences in priorities for patients and their caregivers when undergoing treatment for non–small cell lung cancer.

Survival rates among breast cancer patients whose cancer is detected before it spreads are high, between 86% and 89%. Yet if the cancer is detected after the cancer cells have migrated, that number ...

In its first global phase 3 readout, Akeso and Summit Therapeutics’ closely watched PD-1xVEGF bispecific antibody ivonescimab ...